Bristol-Myers Upgraded On Immuno-Oncology Growth Prospects At Morgan Stanley

Morgan Stanley analyst David Risinger upgraded Bristol-Myers to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market.